Floatz logo

Inv-6452

Advanced Solid Cancers

Shenzhen Ionova Life Sciences Co., Ltd.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Advanced Solid Cancers cohort.

Asset / SponsorPhaseRating
prl3-zumab
Intra-IMMUSG Pte Ltd
Phase 2/3B
FENTANYL
Gachon University Gil Medical Center
Phase 2B
Oxycodone
Gachon University Gil Medical Center
Phase 2B
Zalifrelimab
Agenus Inc.
Phase 1/2CCC
BMS-863233
Bristol-Myers Squibb
Phase 1/2CC

View all 22 →

Same molecule, other indications

Inv-6452 is also rated in:

breast cancerDormant
CC
Indicative ·
47 / 100
View asset →
endometrial carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
ovarian cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →